A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
Launched by ELI LILLY AND COMPANY · Apr 28, 2025
Trial Information
Current as of June 08, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The ATTAIN-Hypertension study is a clinical trial looking at a new medication called orforglipron (LY3502970) to see how well it works in lowering high blood pressure, also known as hypertension, in people who are overweight or obese. This is a Phase 3 trial, which means it’s one of the final steps in testing this medication before it can potentially be approved for general use. The study is not yet recruiting participants, but when it does, it will include men and women aged 65 to 74.
To be eligible for this trial, participants will need to meet certain criteria outlined in a larger study called the GZPL master protocol. While specifics are not detailed here, generally, potential participants will need to have a confirmed diagnosis of hypertension and be classified as overweight or obese. Those who join the study can expect to receive the medication orforglipron and will be monitored for its effects on their blood pressure and overall health. This trial could help determine if orforglipron is a safe and effective treatment option for managing high blood pressure in individuals who are overweight.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • refer to the GZPL master protocol study for screening eligibility.
- Exclusion Criteria:
- • refer to the GZPL master protocol study for screening eligibility.
About Eli Lilly And Company
Eli Lilly and Company is a global healthcare leader dedicated to creating innovative medicines that improve patient outcomes across a range of therapeutic areas, including diabetes, oncology, immunology, and neurodegenerative diseases. With a rich history of scientific research and a commitment to advancing healthcare, Lilly invests significantly in clinical trials to develop new treatments and enhance existing therapies. The company prioritizes patient safety and ethical standards in its clinical research, fostering collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality, evidence-based solutions that address unmet medical needs worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Ogden, Utah, United States
Richmond, Virginia, United States
Honolulu, Hawaii, United States
Newport News, Virginia, United States
Berlin, , Germany
Waterbury, Connecticut, United States
Phoenix, Arizona, United States
Wuxi, Jiangsu, China
Chengdu, Sichuan, China
Northridge, California, United States
Sevilla, Andalucía, Spain
Bydgoszcz, Kujawsko Pomorskie, Poland
Chuo Ku, Tokyo, Japan
Siping, Jilin, China
Saint Peters, Missouri, United States
Columbus, Ohio, United States
Lishui, Zhejiang, China
Jinan, Shandong, China
Boca Raton, Florida, United States
Mckinney, Texas, United States
Covina, California, United States
Chuo Ku, Tokyo, Japan
Saratoga Springs, New York, United States
Bhubaneswar, Odisha, India
Oldenburg, Schleswig Holstein, Germany
New Delhi, Delhi, India
Sevilla, , Spain
Las Vegas, Nevada, United States
Troy, Michigan, United States
Essen, Nordrhein Westfalen, Germany
Leipzig, Sachsen, Germany
Athens, Attikí, Greece
Wroclaw, Dolnośląskie, Poland
Buenos Aires, , Argentina
Luoyang Shi, Henan, China
Bangalore, Karnataka, India
Yamato Shi, Kanagawa, Japan
Las Vegas, Nevada, United States
North Richland Hills, Texas, United States
Redmond, Washington, United States
Port Charlotte, Florida, United States
Kamakura Shi, Kanagawa, Japan
Changchun, Jilin, China
Mauldin, South Carolina, United States
Dorado, , Puerto Rico
Ponce, , Puerto Rico
Białystok, Podlaskie, Poland
Beijing, Beijing, China
Dresden, Sachsen, Germany
Praha 5, , Czechia
Córdoba, , Argentina
Pardubice V, Pardubice, Czechia
Granadero Baigorria, Santa Fe, Argentina
Rosario, Santa Fe, Argentina
Rosario, Santa Fe, Argentina
Xian, Shaanxi, China
Bad Homburg, Hessen, Germany
Ioannina, Ioánnina, Greece
León, Castilla Y León, Spain
Jacksonville, Florida, United States
Piotrkow Trybunalski, łódzkie, Poland
Changde, Hunan, China
Dayton, Ohio, United States
Thessaloniki, Thessaloníki, Greece
Przemysl, Podkarpackie, Poland
Buenos Aires, , Argentina
Rochester, New York, United States
Wenatchee, Washington, United States
Thessaloniki, Thessaloníki, Greece
New Bedford, Massachusetts, United States
Köln, Nordrhein Westfalen, Germany
Dresden, Sachsen, Germany
Baltimore, Maryland, United States
Warsaw, Mazowieckie, Poland
Tarnów, Małopolskie, Poland
Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina
Lishui City, Zhejiang, China
Prague, Praha 12, Czechia
A Coruña, A Coruña [La Coruña], Spain
Athens, Attikí (Region), Greece
Shanghai, Shanghai, China
Brandon, Florida, United States
Hodonin, Hodonín, Czechia
Sun City Center, Florida, United States
La Coruña, A Coruña [La Coruña], Spain
Centelles, Barcelona [Barcelona], Spain
Tigard, Oregon, United States
Manassas, Virginia, United States
San Isidro, Buenos Aires, Argentina
Chongqing, Chongqing, China
Brno, Brno Město, Czechia
Brno, Brno Město, Czechia
Ostrava, Moravskoslezský Kraj, Czechia
Ledec Nad Sazavou, Vysočina, Czechia
Praha 4, , Czechia
Leipzig, Sachsen, Germany
Thessaloniki, Thessaloníki, Greece
Ulhasnagar, Maharashtra, India
Matsuyama, Ehime, Japan
Bydgoszcz, Kujawsko Pomorskie, Poland
Barcelona, Barcelona [Barcelona], Spain
Patients applied
Trial Officials
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Eli Lilly and Company
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported